Navigation Links
Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
Date:2/24/2013

EAST HANOVER, N.J., Feb. 24, 2013 /PRNewswire/ -- Late-breaking results from ASTERIA II, a Phase III placebo-controlled study, showed positive results in patients with moderate to severe chronic idiopathic urticaria (CIU), referred to as chronic spontaneous urticaria (CSU) outside the United States, who remained symptomatic despite treatment with approved antihistamine doses. The data were published today in the New England Journal of Medicine and will be presented tomorrow at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting in San Antonio, Texas. Omalizumab is not indicated for CIU.

The primary endpoint was measured using a 21-point scale known as a weekly Itch Severity Score (ISS). The study met its primary endpoint, showing that omalizumab given at doses of 150 mg and 300 mg every four weeks led to significant improvement from baseline at Week 12 in the mean weekly ISS from baseline (approximately 14 in all treatment groups) by 8.1 (p=0.001) and 9.8 (p<0.001), respectively, compared to a 5.1 improvement in patients on placebo. The omalizumab 75 mg dose group did not demonstrate statistical significance compared to placebo for the primary endpoint. All eight pre-specified secondary endpoints in the ASTERIA II trial were met for the 150 mg and 300 mg doses, except for the 150 mg dose that did not show a significant difference from placebo in the proportion of angioedema-free days from Week 4 to Week 12 of therapy.

CIU is a distressing skin condition characterized by red, swollen, itchy and sometimes painful hives on the skin, spontaneously presenting and reoccurring for more than six weeks. At any given time, the prevalence of CIU is 0.5% to 1% worldwide. While antihistamines are used first to treat CIU, more than 50% of patients are unable to achieve symptom relief with approved doses.

"These results indicate that omal
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Novartis Pharma Logistics, Inc. voluntarily recalling in Jamaica select lots of certain over-the-counter products due to bottle closure defect
2. Novartis Pharma Logistics, Inc. voluntarily recalling in Trinidad & Tobago select lots of certain over-the-counter products due to bottle closure defect
3. Novartis Pharma Logistics, Inc. voluntarily recalling in Curacao select lots of certain over-the-counter products due to bottle closure defect
4. Novartis Pharma Logistics, Inc. voluntarily recalling in Aruba select lots of certain over-the-counter products due to bottle closure defect
5. Novartis Pharma Logistics, Inc. voluntarily recalling in Barbados select lots of certain over-the-counter products due to bottle closure defect
6. Continued Uptake of Novartis/Incytes Jakafi Will Be the Greatest Driver of Growth in the Myelofibrosis Therapy Market
7. Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at ASH and SABCS
8. Thesan Pharmaceuticals offentliggør første runde af venturefinansieringen ledt af Novo Ventures og Novartis Venture Funds i fællesskab
9. Thesan Pharmaceuticals annuncia un finanziamento di serie A co-gestito da Novo Ventures e Novartis Venture Funds
10. Thesan Pharmaceuticals gibt Serie-A-Finanzierung unter gemeinsamer Führung von Novo Ventures und Novartis Venture Funds bekannt
11. Thesan Pharmaceuticals Announces Series A Funding Co-Led By Novo Ventures And Novartis Venture Funds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Research and Markets  has announced the ... report to their offering. ... diagnose, monitor, and assess medical conditions, diseases, or infections ... for earlier and more targeted treatment. These tests are ... results. This kind of diagnostics provides early detection of ...
(Date:7/22/2014)... 22, 2014  Eyeon Therapeutics has received a Notice ... on a charged hydrophilic polymer developed at Particles Sciences, ... shown to be safe and effective in a small ... states, "This first set of claims around the polymer ... moving this technology into the commercial phase.  We have ...
(Date:7/22/2014)... Calif. , July 22, 2014  Based ... imaging (MRI) market, Frost & Sullivan recognizes Siemens ... Product Leadership. Siemens Healthcare,s FREEZEit solution, which employs ... need for robust and motion-insensitive imaging. The solution,s ... the evolution of body MRI imaging in the ...
Breaking Medicine Technology:Global IVD Market 2014-2018: Key Vendors are Abbott Laboratories, Johnson & Johnson, Roche Diagnostics and Siemens Healthcare 2Global IVD Market 2014-2018: Key Vendors are Abbott Laboratories, Johnson & Johnson, Roche Diagnostics and Siemens Healthcare 3Particle Sciences and Eyeon Therapeutics Receive Patent on Novel Dry Eye Technology 2Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 2Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 3Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 4
... Statistically Significant Clinical Results for,SB-509 in Development ... 22, 2007 /PRNewswire-FirstCall/ -- Sangamo,BioSciences, Inc. announced ... data from its ZFP Therapeutic(TM) program at ... Association,(ADA). As disclosed in an oral presentation ...
... 2007--Gilead,Sciences, Inc. (Nasdaq:GILD) today announced that Study ... company's once-daily,anti-HIV drug Viread(R) (tenofovir disoproxil fumarate ... treatment for chronic hepatitis B virus,(HBV) infection, ... show,that Viread is non-inferior to the company's ...
Cached Medicine Technology:Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 2Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 3Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 4Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 5Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 6Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 7Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 8Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 9Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 2Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 3Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 6
(Date:7/22/2014)... 2014 The 2014 Warrior-Family Symposium ... Reagan Building and International Trade Center in Washington, ... and Civilian Communities,” will be held from 8:30 ... a.m.) and cohosted by the Military Officers Association ... Association (NDIA). USAA is the Executive Sponsor of ...
(Date:7/22/2014)... Steven Reinberg HealthDay Reporter ... obese during pregnancy may be more likely to have children ... "We found that, compared with children born from mothers of ... pregnancy had up to 20 to 30 percent higher odds ... professor of pediatrics at Children,s Hospital of Pittsburgh. Forno,s ...
(Date:7/22/2014)... of research at the University of Utah,s John A. ... Society of Eye Research (ISER) as the recipient of ... International Award in Retina Research., The award recognizes lifetime ... significant contribution to the understanding of vitreoretinal diseases or ... the ISER Biennial Meeting in San Francisco, where Marc ...
(Date:7/22/2014)... DC (PRWEB) July 22, 2014 ... USA, launched updated payment app for Forte Payment System. ... debit and ACH payments on iPhone, iPod and iPad. ... and has been recently updated by SIMpalm. This update ... app is currently supported on iOS 4.3 and is ...
(Date:7/22/2014)... Washington, DC (PRWEB) July 22, 2014 Ticket ... vs. Inter Milan tickets at Fedex Field in Landover, MD. ... Sates to be a fan of international soccer. After the success ... in Brazil, soccer fever is alive and well. One way that ... hunger for the sport is with the 2014 Guinness International Champions ...
Breaking Medicine News(10 mins):Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 2Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 3Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 2Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 3Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 2Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 3Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 2Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 3
... The former director of information technology for a ... guilty plea to intruding into her former employer,s computer ... A. Breuer, acting U.S. Attorney Tim Johnson and FBI ... a hearing before U.S. District Judge David Hittner, Danielle ...
... Aranesp, experts say, , , THURSDAY, April 30 (HealthDay News) ... such as Procrit and Aranesp, often used by cancer ... of death and serious adverse events such as blood ... also been associated in prior studies with increased risk ...
... Zealand, April 30 As the world mourns the deaths ... outside of Mexican soil, the World Health Organization has raised ... being confirmed in California, Texas, New York, Maine and Massachusetts, ... New Zealand, people all over the globe are beginning to ...
... As an expectant mother, her first official Mother,s Day doesn,t ... Here are four unique ideas to make this Mother,s Day unforgettable ... rest, this can be a vexing time. She knows it ... off her feet, but she is still very aware that laundry ...
... A new poll by the Pew Research Center,s Forum ... Catholics who have heard about the issue support President ... divisions exist between the most-observant Catholics and those who ... over their assessment of Obama,s job performance.Conducted from April ...
... April 30 Cadence ... company focused on in-licensing, developing and commercializing proprietary product ... announced that it will release its first quarter ended ... on Thursday, May 7, 2009. Cadence management will host ...
Cached Medicine News:Health News:Computer Administrator Pleads Guilty to Hacking Former Employer's Computer System 2Health News:Anemia Drugs May Raise Death Risk in Cancer Patients 2Health News:Anemia Drugs May Raise Death Risk in Cancer Patients 3Health News:Anemia Drugs May Raise Death Risk in Cancer Patients 4Health News:All Natural System Sweeps Swine Flu Out with the Trash 2Health News:Four Unique Gifts for Expectant Moms Includes New Technology That Enhances Pre-Natal Bonding 2Health News:New Poll on Obama, Catholics and the Notre Dame Commencement Finds Deep Divisions Among Catholics 2
Micro instruments designed to provide maximum grasping, resecting capability, and excellent maneuverability for easy access to tight, small joints (wrist, elbow, and ankle).,Features pinless hinge d...
... LactoSorb® No-Profile Screw and Washer ... for multiple soft tissue re-attachments ... No-Profile Screw and washer provides ... a standard screw and washer ...
... The Stryker Inter-Lock™ System ... surgery at the tibial fixation ... backup fixation into one implant. ... and can be used routinely ...
The Stryker Bioabsorbable Wedge Interference Screw is made of Poly-L Lactic Acid (PLLA). The patented wedge design makes it perfect for cruciate reconstruction and is indicated for BTB and soft tissu...
Medicine Products: